Clinical trial · Interventional
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib. 2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Craniopharyngiomas | Craniopharyngioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anlotinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A single-center, open-label, single-arm, experimental clinical trial without any control group
- description
- This is a single-center, open-label, single-arm, experimental clinical trial without any control group. The study was conducted in patients with recurrent craniopharyngiomas
- interventionNames
- Drug: Anlotinib
Primary outcomes (1)
- measure
- Measurement of tumor volume on imaging (MRI)
- timeFrame
- Through study completion, an average of 1 year
- description
- Measurement of tumor volume on imaging (MRI): A\*B\*C/2 (A,B,C are the maximum length, width, and height of the tumor, respectively)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-75 years old, regardless of gender 2. recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data 3. predominantly cystic or solid recurrence of the tumor 4. measurable lesions (according to the RECIST criteria) 5. Karnofsky score ≥ 70, expected survival ≥ 3 months 6. laboratory parameters (liver and kidney function, blood tests, etc.) within the normal range or under control 7. signed informed consent and willing to participate in the study Exclusion Criteria: 1. Have a combination of other intracranial tumors or severe brain lesions 2. primary craniopharyngioma 3. have severe uncontrolled heart, lung, kidney, or liver disease 4. children, pregnant or breastfeeding women 5. prior treatment with the same investigational drug 6. active infections, including HIV, HBV, or HCV infections 7. patients who do not meet the contraindications to the medication 8. have a history of severe allergy to the investigational drug 9. have psychiatric illnesses or cognitive impairments and unable to complete follow-up visits or understand the purpose of the study
References
Publications (0)
Data not yet available